Novartis vet O'Dowd takes the helm at Neon; FDA slaps a hold on Cel-Sci's PhIII cancer study
Cambridge, MA-based Neon Therapeutics is celebrating its first birthday with a new CEO appointment. In classic Third Rock fashion the neoantigen biotech got started with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.